For this purpose, we investigated plasma NTA-tau in the Swedish BioFINDER-1 and BioFINDER-2 studies, both well-characterized by clinically validated fluid and imaging biomarkers, including cross-sectional and longitudinal samples of participants across the AD continuum, non-AD cases and control individuals. The gene discussed is MAPT; the disease is Alzheimer disease.